论文部分内容阅读
目的分析和评价联用母牛分枝杆菌菌苗(微卡菌苗)治疗耐多药肺结核(MDR-TB)的近远期疗效。方法将81例MDR-TB患者随机分为治疗组(A组,40例)和对照组(B组,41例)。2组的化疗方案均为3DLVKZ/15DLV,A组加用微卡菌苗治疗12月,B组不用微卡菌苗。结果疗程结束后,A组和B组痰菌阴转率分别为86.5%和58.5%,A组X线胸片显示病灶吸收、空洞缩小及关闭速度明显高于B组(P<0.05)。随访2年,A组和B组的痰菌复阳率分别为7.5%和14.6%。结论治疗组治疗耐多药肺结核病的近期和远期疗效明显高于对照组,且副作用小,值得推广应用。
Objective To analyze and evaluate the short-term and long-term effects of combined use of Mycobacterium vaccae vaccine (Mika vaccine) in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB). Methods 81 patients with MDR-TB were randomly divided into treatment group (A group, 40 cases) and control group (B group, 41 cases). The two groups of chemotherapy were 3DLVKZ / 15DLV, A group plus micro-card vaccine treatment of 12 months, B group without micro-card vaccine. Results After the course of treatment, the sputum negative conversion rates in group A and group B were 86.5% and 58.5%, respectively. A group of X - ray showed that the lesion absorption, voids shrinkage and closing speed were significantly higher than those in group B (P <0.05). After 2 years of follow-up, the sputum recovery rates in group A and group B were 7.5% and 14.6%, respectively. Conclusions The short-term and long-term curative effects of MDR-TB treatment in treatment group are obviously higher than those in control group, and the side effects are small and worthy of promotion and application.